Since 2012 when the first CFTR modulator, Kalydeco, was approved, modulator therapy has transformed cystic fibrosis care. By the end of 2024, 24,524 people with CF in the United States were prescribed Trikafta, according to data from the Patient Registry. However, 7.3% of people with CF were still not eligible for any CFTR modulators due to their age or genotype. For them, our work is not done. We are committed to finding a cure and advancing therapies for every person with CF. | Cystic Fibrosis

EXCITING NEWS!👏👏👏 Vertex just announced U.S. FDA approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in children with Cystic Fibrosis ages 6 through 11 with certain mutations. This is a game changer. We couldn’t be more excited for this groundbreaking treatment to expand to children! Head to bit.ly/3cz0nxy to read the full announcement! | Claire's Place Foundation, Inc.